- Product Partners
- Supplements Facts
- Scientific References
- Client Reviews
Protect Against Mental Decline with Stabilized TruePS™!
Phosphatidylserine (PS) is one of the body’s essential building blocks. It’s naturally found in the cell membrane and particularly abundant in the brain. In general, the human brain is very rich in lipid (fat) content. And PS accounts for 18% of all phospholipids in the brain – indicating its importance to normal cognitive function.
PS is crucial to the structure and function of nerve cells and plays a key role in cell-to-cell communication, information transfer, signaling and more.
The daily intake of PS is reduced in modern diets – largely due to a greater focus on lower fat foods. For example, it’s estimated that the average individual consumed 250mg of PS daily from food prior to the 1980s. Today the average person gets only about 130mg of PS daily from food (and a vegetarian diet provides only about 50mg/day).
Clinical studies demonstrate beneficial effects for supplementing our daily diet with 100mg to 300mg per day of PS (each TruePS™ soft gel provides 100mg of stabilized Sharp PS®).
PS benefits haven been demonstrated in over 30 clinical studies addressing the entire human life cycle – from children to adults to seniors. Here’s a summary of the PS findings:
- May help slow age-related mental decline, improving memory, attention and concentration.
- Helps improve mood and symptoms of anxiety and stress.
- May reduce risk of cognitive dysfunction and decrease loss of brain cells.
These benefits are possible only if you’re using a “stabilized” PS supplement. Unfortunately, PS is highly unstable and prone to degradation (and taking degraded PS won’t help you). In fact, a recent study showed a standard PS product degraded by 20% within 4.5 months of encapsulation.
TruePS™ overcomes this concern by using a proven stabilization process. Shelf life studies have shown that even after 24 months, the PS showed absolutely no degradation. It was as potent at month 24 as it was the day the soft gel was made.
The Importance of Choosing a “Stabilized” Phosphatidylserine (PS) Supplement
Phosphatidylserine (PS) is a phospholipid that is a major component of cell membranes, making it a highly valuable nutrient for enhancing cognitive function. Without sufficient levels of PS, brain cells do not transmit nerve impulses properly.
TruePS™ is made with Sharp PS® - a high purity phosphatidylserine (PS) brand, developed and produced in Israel by Enzymotec Ltd. under the highest quality and safety standards.
In clinical testing, Sharp PS® has been shown to have a positive effect on memory recognition, memory recall, executive functions and mental flexibility.
Even though Sharp PS® is a very high quality PS, it like other phosphatidylserine is highly unstable and prone to degradation over time.
In fact, a recent shelf-life study, performed on a standard fluid PS material by an independent international laboratory for phospholipid analysis, showed dismaying results. Within 12 weeks of encapsulation, the standard fluid PS material had degraded by 10%. Within 18 weeks, it had degraded by nearly 20%.
As you might expect, when PS degrades, it is of little value to your brain cells.
To overcome the issue of PS stability, Soft Gel Technologies® has developed a method to enhance Sharp PS® using an exclusive fluid dispersion (provided as finished dosage soft gels) that has enviable stability.
Shelf-life studies on this stabilized Sharp PS®, performed by the same independent laboratory mentioned above, found that even after 24 months, the material showed absolutely no degradation. It was as potent at month 24 as it was the day it was encapsulated.
This allows you to use every bottle of TruePS™ with confidence, knowing that the PS is active and able to provide maximum benefits.
Dietary Supplement / 30 Softgels
Serving Size: 1 Softgel
Servings per Container: 30
|Amount Per Serving||% Daily Value|
|Phosphatidylserine ComplexSharp-PS®||500 Mg||N/A*|
* Daily Value not established.
Other Ingredients: Gelatin, glycerin, polyglycitol syrup, purified water. Contains Soy.
Sharp-PS® is a registered trademark of Enzymotec Ltd.
If you aren't currently using TruePS™, for most immediate results, it is recommended that you take three (3) TruePS™ softgels a day for the first 4 weeks. Thereafter, a maintenance serving of one (1) TruePS™ softgel a day is typically recommended.
TruePS™ is a highly purified and stabilized phosphatidylserine (PS) that supports brain health.†
Keep out of reach of children.
Store at 15-30° C (59-86° F).
Protect from heat, light and moisture.
Do not purchase if seal is broken.
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Assembled in the USA
Manufactured for and Distributed by: NatureCity®
Boca Raton, FL 33487 www.naturecity.com
To re-order call toll free 1-800-593-2563
Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S. “The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study.” Journal of Clinical Interventions in Aging. 2013;8:557-63.
Richter Y, Herzog Y, Eyal I, Cohen T. Cognitex supplementation in elderly adults with memory complaints: an uncontrolled open label trial. J Diet Suppl 2011 Jun; 8(2):158-68.
Richter Y, Herzog Y, Cohen T, Steinhart Y. “The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study.” Journal of Clinical Interventions in Aging. 2010; 5: 313–316.
Vaisman N. Phosphatidylserine may improve cognitive abilities in elderly with memory complaints: an open label trial – In preparation.
Hirayama S, Terasawa K, Rabeler R, Hirayama T, Inoue T, Tatsumi Y, Purpura M, Jäger R. “The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial.” Journal of Human Nutrition and Dietetics. 2014 Apr;27 Suppl 2:284-91.
Yong T, Qianyong Z, Mantian M, Gang H, Jing W. Research on human memory enhancement by phosphatidylserine fortified milk. Chongqing Medicine. 2011; 30:3022-23 3026.
Parker AG, Gordon J, Thornton A, Byars A, Lubker J, Bartlett M, Byrd M, Oliver J, Simbo S, Rasmussen C, Greenwood M, Kreider RB. “The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise.” Journal of the International Society of Sports Nutrition. 2011 Oct 21;8:16.
Gindin J, Novikov M, Dedar D, Walter- Ginzburg A, Naor S, Levi S. “The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly.” The Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital, Rehovot, Isryongael. Unpublished report; 2009.
Schreiber, S.,0. Kampf-Sherf, M. Gorfine, D. Kelly, Y. Oppenheim, B. Lerer.. “An open trial of plant-source derived Phosphatidylserine for the treatment of age-related cognitive decline.” Israel Journal of Psychiatry and Related Sciences 2000 37: 302-307.
Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. “Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints.” Journal of Clinical Biochemistry and Nutrition. 2010 Nov; 47(3): 246–255.
Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. “Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial.” Dementia and Geriatric Cognitive Disorders. 2010;29(5):467-74.
Starks M, Starks S, Kingsley M, Purpura M, Jäger R. “The effects of phosphatidylserine on endocrine response to moderate intensity exercise.” 2008 Jul 28;5:11.
Baumeister J, Barthel T, Geiss KR, Weiss M. “Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress.” Nutritional Neuroscience. 2008 Jun;11(3):103-10.
Jäger R, Purpura M, Geiss K, Weiss M, Baumeister J, Amatulli F, Schröder L, Herwegen H. “The effect of phosphatidylserine on golf performance.” Journal of the International Society of Sports Nutrition. 2007 Dec; 4:23.
Jorissen, B.L., F. Brouns, M.P.J. van Boxtel, R.W.H.M. Ponds. F.R.J. Verhey, J. Joiles, W.J. Riedel. ”The influence of soy-derived phosphatidylserine on cognition in age associated memory impairment.” Nutritional Neuroscience 2001.4: 121-134.
Crook, T. H. “Treatment of age-related cognitive decline: Effects of phosphatidylserine in anti-aging medical therapeutics”, Vol 11, edited by R.M. Klatz, Health Quest Publications, 1998.Chicago, pp. 20-29.
Heiss, W.-D., J. Kessler, R. Mielke, B. Szelies, K. Herholz. “Long-term effects of phosphatidylserine, pyritinol, and cognition training in Alzheimer's disease.” Dementia 1994. 5: 88-98.
Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. “Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.” Aging (Milano). 1993 Apr;5(2):123-33.
Crook T, Petrie W, Wells C, Massari DC. “Effects of phosphatidylserine in Alzheimer's disease.” Psychopharmacology Bulletin. 1992;28(1):61-6.
Engel, R.R., W. Satzger,W. Gunther,N. Kathmann,D. Bove, S.Gerke, U.Munch, H. Hippius. “Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type.” European Neuropsychopharmacol 1992.2:149-1 55.
Crook T, Tinklenberg J, Yesavage J, Petrie W, Nunzi M, Massari D. “Effects of phosphatidylserine in age-associated memory impairment.” Neurology. May 1991 vol. 41 no. 5 644-649.
Klinkhammer P. Szelies B. Heiss W. “Effect of Phosphatidylserine on Cerebral Glucose Metabolism in Alzheimer's Disease.” Dementia and Geriatric Cognitive Disorders. 1990;1:197–201.
Puca, F.M., M.A. Bavarese, M.G. Minervini. “Exploratory trial of L phosphatidylserine efficacy in mildly demented patients.” Clinical Trials Journal 1987. 24: 94- 98.
Maggioni, M., G.B. Picotti, G.P. Bondiolotti, A. Panerai, T. Cenacchi, P. Nobile, F. Brambilla. “Effects of phosphatidylserine therapy in geriatric patients with depressive disorders.” Acta Psychiatrica Scandinavica 1990. 8 1 : 265-270.
Rabboni, M., F.S. Maggioni, A. Giannelli, L. Beinat. “Neuroendocrine and behavioral effects of phosphatidylserine in elderly patients with abiotrophic or vascular dementia or mild depression.” Clinical Trials Journal 1990. 27: 230-240.
Hershkowitz, M., M. Fisher, D. Bobrov, M. Rabinowitz. “Long-term treatment of dementia of Alzheimer type with phosphatidylserine: Effect on cognitive functioning and performance in daily life. In: Phospholipids in the Nervous System: Biochemical and Molecular Pathology. Eds.” N.G. Bazan, L.A. Horrocks, G. Toffano (eds). Liviana Press, Padova; 1989. pp. 279-288.
Amaducci, L. and the SMID group. “Phosphatidylserine in the treatment of Alzheimer’s disease: Results of a multicenter study.” Psychopharmacol Bulletin 1988.24: 130-134.
Allegro, L., V. Favaretto, G. Ziliotto. “Oral phosphatidylserine in elderly patients with cognitive deterioration. An open study.” Clinical Trials Journal 1987.24: 104-108.
Granata, Q., J. Di Michele. “Phosphatidylserine in elderly patients.” Clinical Trials Journal 1987. 24: 99-103.
Caffarra, P., V. Santamaria. “The effects of phosphatidylserine in patients with mild cognitive decline.” Clinical Trials Journal 1987.24: 109 - 114.
Sinforiani, E., C. Agostinis, P. Merlo, S. Gualtieri, M. Mauri, A. Mancuso. “Cognitive decline in ageing brain. Therapeutic approach with phosphatidylserine.” Clinical Trials Journal.1987. 24: 115-124.
Palmieri, G., R. Palmieri, M.R. Inzoll, A.M. Agrati, A Vargiu. “Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration.” Clinica Trials Journal 1987. 24: 73-83.
Villardita, J.C., S. Grioli, G. Salmeri, F. Nicoletti, G. Pennisi. “Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration” Clinical Trials Journal 1987. 24: 84-93.
Delwaide, P.J., A.M.Gyselynck-Mamboug, A. Hurlet, M. Ylieff. “Double-blind randomized controlled study of phosphatidylserine in senile demented patients.” Acta Neurologrca Scandinavica 1986. 73: 136-140.